We reported that in afatinib-resistant sublines derived from the lung cancer cell line PC9 that harbors an activating EGFR mutation, the levels of multiple EGFR family proteins are markedly reduced and accompanied by compensatory activation of an FGF2/FGFR1 autocrine signaling pathway [29]. This evidence concerns the gene EGFR and lung cancer.